

PRELIMINARY AMENDMENT

IN THE SPECIFICATION:

Please enter the Sequence Listing on page 42, after the Claims.

STATEMENT UNDER 37 C.F.R. § 1.821(f)

In accordance with 37 CFR §§ 1.821-1.825, Applicants hereby state that the content of the paper and computer-readable copies of the sequence listing submitted in accordance with 37 CFR §§ 1.82(c) and (e) respectively, are the same. Applicants hereby state that this submission, filed in accordance with 37 CFR § 1.82 (g), does not introduce new matter.

REMARKS


Applicants received a Notice of Defective Response for the above-identified application in which Applicants were notified that each of Sequence Identifiers 10-19 were missing the required field for 220 and 223. Applicants have submitted a Sequence Listing in which the required field for 220 is present (intentionally left blank) as is the required field for 223 (designated Synthetic Primer to describe the source of the Artificial Sequence for each of Sequence Identifiers 10-19. Consistent with the Sequence Listing filed concurrently herewith, applicants amend the Specification of the instant application as indicated above. No new matter is believed to be at issue, and entry and early action on the merits are respectfully requested.

AUTHORIZATION

The Commissioner is hereby authorized to charge any deficiencies in the associated fees which may be required for this Preliminary Amendment, or credit any overpayment Deposit Account No. 19-5127 (7049312001).

Respectfully submitted,

Bingham McCutchen LLP
3000 K Street, N.W., Suite 300
Washington, D.C. 20007
(202)424-7500
(202)295-8478


Serge Sira, Ph.D
Registration No. 39,445

Dated: September 14, 2006

Page 2 of 2